AIM vs. PDSB, IMMX, OVID, IVVD, ALVR, RPTX, FGEN, SPRO, ICCC, and ACHL
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Ovid Therapeutics (OVID), Invivyd (IVVD), AlloVir (ALVR), Repare Therapeutics (RPTX), FibroGen (FGEN), Spero Therapeutics (SPRO), ImmuCell (ICCC), and Achilles Therapeutics (ACHL). These companies are all part of the "pharmaceutical products" industry.
AIM ImmunoTech vs.
PDS Biotechnology (NASDAQ:PDSB) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
PDS Biotechnology has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500.
PDS Biotechnology received 12 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 83.10% of users gave AIM ImmunoTech an outperform vote while only 69.61% of users gave PDS Biotechnology an outperform vote.
26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 9.5% of PDS Biotechnology shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
PDS Biotechnology has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. PDS Biotechnology's return on equity of -139.57% beat AIM ImmunoTech's return on equity.
AIM ImmunoTech has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology presently has a consensus target price of $11.67, indicating a potential upside of 667.54%. AIM ImmunoTech has a consensus target price of $2.75, indicating a potential upside of 1,280.52%. Given AIM ImmunoTech's higher possible upside, analysts clearly believe AIM ImmunoTech is more favorable than PDS Biotechnology.
In the previous week, AIM ImmunoTech had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for AIM ImmunoTech and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat AIM ImmunoTech's score of 0.45 indicating that PDS Biotechnology is being referred to more favorably in the media.
Summary
PDS Biotechnology beats AIM ImmunoTech on 11 of the 18 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
This page (NYSE:AIM) was last updated on 1/30/2025 by MarketBeat.com Staff
